SEARCH · PubMed Health
Results for “Tablets, Enteric-Coated”
Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.
Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.
[Clinical treatment of inflammatory and benign ulcerous diseases of the stomach and duodenum with a new combination preparation (Aci-Tensilan) (author's transl)].
A gastroduodenal combination preparation was introduced at a deliberately high dosage into a clinical treatment schema. A marked improvement of the subjective symptoms already appeared after a short treatment in hospital, pain in particular being rapidly affected. Younger patients tolerated the preparation excellently, older ones had a marked sedation. Because of the danger of concealment, stenoses in the region of the gastrointestinal tract, ileus and preileus are particular contraindications. The dosage of 3 X 3 to 3 X 4 dragees should be reserved for hospital treatment. The dosage of 3 X 1 dragee for ambulant practice and also for prolonged therapy (ca. 6-8 weeks) is unobjectionable, reference being made to possible initial tiredness and disturbances of accomodation.
[Dosage of allopurinol. A comparative cross-over study of daily single and multiple doses].
Explore the source record for details and available documents.
[Potassium chloride and non-specific ulcers in the small intestine].
Gut toxicity due to potassium chloride preparations is well known, but there is little information concerning side effects of the newer slow release preparations. Small bowel ulceration due to the new slow release formulation is described. As far as the authors are aware this is the first such case published in Switzerland.
[Influence of formulation of enteric coated tablets on the bioavailability of the drug. 4th Part: Influence of the enteric polymer dissolution pH on the "in vivo" absorption of aspirin from coated tablets (author's transl)].
Explore the source record for details and available documents.
[Absorption, excretion, and clinical effects of L-dopa preparation with superenteric coating in parkinsonism (author's transl)].
Explore the source record for details and available documents.
Preparation and evaluation of free films: influence of method of preparation and solvent composition upon the permeability.
Explore the source record for details and available documents.
[Coating IV. Study on solutions and cellulose films. Influence of plasticizers].
Explore the source record for details and available documents.
[On the development of oral preparations of the combination sulfamoxole/trimethoprim (CN 3123) (author's transl)].
Within the broad range of activities in pharmaceutical research, the technological development and analytical evaluation of a new drug formulation represent only one step. The pharmaceutical development of three oral formulations of a combination product containing N1-(4,5-dimethyl-2-oxazolyl)-sulfanilamide (sulfamoxole) and 2,4-diamino-5-(3,4,5-trimethoxy-benzyl)-pyrimidine (trimethoprim) in a 5:1 ratio (investigational drug CN 3123; Nevin; Supristol), which was based on the physico-chemical characteristics of the 2 active substances, is presented. The various chemical and physical tests conducted with the drug formulations are described. The pharmaceutical or in-vitro availabilities (dissolution rate) of the active ingredients were determined by way of release-rate profiles, both of the active ingredients alone and in their final formulations. Also presented are the results of plasma level determinations following oral administration of film-coated tablets and a suspension. Finally, preliminary results of extensive stability tests with the three drug formulations are discussed.
[Study of fluorofur absorption and distribution when administered intravenously and perorally in various drug forms].
Explore the source record for details and available documents.
[Influence of formulation of enterosoluble preparations on the physiologic disposition of the active principle. Part III. Establishment of quantitative correlations between the rate of dissolution in vitro of the active principle and its absorption characteristics].
Explore the source record for details and available documents.
[Check to myocardial infarct].
Explore the source record for details and available documents.
[Erythromycin stearate Spofa--coated tablets for pediatric practice].
Explore the source record for details and available documents.
Complications of "slow-K" therapy.
(1) The failure of ;Slow-K' tablets to disintegrate prevents rapid release but allows them to be trapped by their bulk in the intestine.(2) Two cases are reported. In the first the tablet was trapped in a caecal diverticulum and the patient developed an abcess. In the second, abdominal pain developed which subsided when ;Slow-K' was stopped. Later ;Slow-K' was again started and the patient developed dysphagia.(3) The possibility of abdominal complications with this treatment should be remembered.(4) Effervescent KC1 preparations may replace ;Slow-K' but KC1 supplementation may be necessary only in cardiac disease.
[From the Adverse Drug Reaction Committee. Potassium chloride--intestinal perforation].
Explore the source record for details and available documents.
Class experiment with student volunteers illustrating the influence of formulation on absorption of aspirin [proceedings].
Explore the source record for details and available documents.
[Influence of formulation of enteric coated tablets on the bioavailability of the drug. 5th Part: Bioavailability of Riboflavin enteric coated tablets (author's transl)].
Explore the source record for details and available documents.
An enteric-coated pancreatic enzyme preparation that works.
A new enteric-coated pancreatic enzyme preparation (microspheres) was compared with traditional enzyme tablets in six subjects with severe exocrine pancreatic insufficiency. The microspheres were found to be as effective as traditional enzyme supplements. In most patients in balance studies, the lowest fecal fat values were obtained with microsphere therapy in spite of a smaller amount of lipase administered (6015 vs 10,800-43,200 lipase units per meal). In contrast to enteric-coated tablets, microspheres can be recommended in the treatment of pancreatic steatorrhea.